Enterprise Value

401.7M

Cash

99.98M

Avg Qtr Burn

-4.20M

Short % of Float

32.53%

Insider Ownership

6.10%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
YUPELRI® (revefenacin) Details
Chronic obstructive pulmonary disease

Approved

Quarterly sales

Approved

Quarterly sales

TRELEGY ELLIPTA Details
Chronic obstructive pulmonary disease (COPD)

Approved

Quarterly sales

AMPRELOXETINE (TD-9855) Details
Multiple System Atrophy, Neurogenic orthostatic hypotension

Phase 3

Data readout

Failed

Discontinued

Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details
Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease

Failed

Discontinued

Failed

Discontinued